223 related articles for article (PubMed ID: 25776035)
21. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
Stuart B; Hendrick FB; Xu J; Dougherty JS
Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
[TBL] [Abstract][Full Text] [Related]
22. Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.
Yazdany J; Tonner C; Schmajuk G; Lin GA; Trivedi AN
Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1447-55. PubMed ID: 25244314
[TBL] [Abstract][Full Text] [Related]
23. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
24. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
25. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
26. Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis.
Dalal DS; Zhang T; Shireman TI
Semin Arthritis Rheum; 2020 Oct; 50(5):822-826. PubMed ID: 32896694
[TBL] [Abstract][Full Text] [Related]
27. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
[TBL] [Abstract][Full Text] [Related]
28. Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.
Davidoff AJ; Hendrick FB; Zeidan AM; Baer MR; Stuart BC; Shenolikar RA; Gore SD
J Oncol Pract; 2015 Mar; 11(2):e190-8. PubMed ID: 25563701
[TBL] [Abstract][Full Text] [Related]
29. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
Cheng LI; Rascati KL
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
Erath A; Dusetzina SB
JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
[TBL] [Abstract][Full Text] [Related]
31. In-gap discounts in Medicare Part D and specialty drug use.
Jung J; Xu WY; Cheong C
Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
[TBL] [Abstract][Full Text] [Related]
32. Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance.
Parasrampuria S; Sen AP; Anderson GF
Am J Manag Care; 2020 Sep; 26(9):388-394. PubMed ID: 32930551
[TBL] [Abstract][Full Text] [Related]
33. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
Bonakdar Tehrani A; Cunningham PJ
Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
[TBL] [Abstract][Full Text] [Related]
34. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
35. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.
Ding Q; Shiltz D; Hossami D; Konieczny AM
Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1231-1241. PubMed ID: 36004551
[TBL] [Abstract][Full Text] [Related]
36. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
37. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries.
Sacks NC; Burgess JF; Cabral HJ; Pizer SD; McDonnell ME
J Gen Intern Med; 2013 Jul; 28(7):876-85. PubMed ID: 23404199
[TBL] [Abstract][Full Text] [Related]
38. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
Karaca-Mandic P; Joyce GF; Goldman DP; Laouri M
Health Serv Res; 2010 Oct; 45(5 Pt 1):1227-50. PubMed ID: 20831715
[TBL] [Abstract][Full Text] [Related]
39. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
